Pharmacy Plus Unveils Duostam, An Innovative Solution for Treating BPH 

 Pharmacy Plus, a leading pharmaceutical company, has launched Duostam, an advanced treatment for Benign Prostatic Hyperplasia (BPH) — also known as prostate enlargement. 

BPH is a non-cancerous condition involving an increase in the size of the prostate gland due to cellular growth.

 At the 97th Pharmaceutical Society of Nigeria Conference in Uyo, Professor Ikenna Nnabugwu highlighted that the prostate is a major contributor to Lower Urinary Tract Symptoms (LUTS) in aging men, with a prevalence of LUTS/BPH reaching approximately 20% in men over 40 years old. 

In response to this significant health concern, Pharmacy Plus has introduced Duostam as a targeted solution for BPH treatment. 

Duostam offers numerous benefits, including Relief from LUTS, Improved patient-reported quality of life (QoL), Slower disease progression, Reduced risk of acute urinary retention (AUR), and Reduced risk of bleeding from an enlarged prostate.

Chukwuemeka Obi, Managing Director of Pharmacy Plus, stated that as a research-driven pharmaceutical company, they are committed to providing effective treatment options for patients.

He assured that Duostam is safe for use, with clinical studies confirming its efficacy when used as prescribed.